| Angioedemas, Hereditary
Berinert vs Ruconest
Side-by-side clinical, coverage, and cost comparison for angioedemas, hereditary.Deep comparison between: Berinert vs Ruconest with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRuconest has a higher rate of injection site reactions vs Berinert based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ruconest but not Berinert, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Berinert
Ruconest
At A Glance
IV injection
C1 esterase inhibitor
IV injection
As needed (up to 2 doses/24 hours)
C1 esterase inhibitor (recombinant)
Indications
- Angioedemas, Hereditary
- Angioedemas, Hereditary
Dosing
Angioedemas, Hereditary 20 IU/kg body weight by slow intravenous injection; doses lower than 20 IU/kg body weight should not be administered.
Angioedemas, Hereditary 50 U/kg IV (max 4200 U) by slow intravenous injection over approximately 5 minutes; a second dose at the same level may be given if symptoms persist; no more than 2 doses within 24 hours.
Contraindications
- Life-threatening hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor preparations
- History of allergy to rabbits or rabbit-derived products
- History of life-threatening immediate hypersensitivity reactions to C1 esterase inhibitor preparations, including anaphylaxis
Adverse Reactions
Most common (>4%) Dysgeusia
Serious Laryngeal edema, facial HAE attacks with laryngeal edema, swelling, exacerbation of hereditary angioedema, laryngospasm
Postmarketing Hypersensitivity/anaphylactic reactions, injection-site pain, injection-site redness, chills, fever, thromboembolism (including basilar artery thrombosis, pulmonary microemboli)
Most common (>=2%) Headache, nausea, diarrhea
Serious Anaphylaxis
Postmarketing Abdominal pain, rash
Pharmacology
C1 esterase inhibitor is a plasma-derived serine protease inhibitor (serpin) that inhibits C1r, C1s, factor XIIa, kallikrein, and factor XIa, regulating the complement, contact (intrinsic coagulation), fibrinolytic, and coagulation cascades; IV replacement in C1-INH-deficient HAE patients suppresses bradykinin generation and reduces vascular permeability.
Recombinant C1 esterase inhibitor (C1INH) that regulates the complement and contact system pathways by irreversibly binding target proteases (activated C1s, kallikrein, factor XIIa, factor XIa), restoring functional C1INH activity and suppressing the bradykinin-mediated vascular permeability increases that underlie HAE attacks.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Berinert
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Ruconest
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (3/12) · Qty limit (9/12)
UnitedHealthcare
Berinert
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (3/8) · Qty limit (0/8)
Ruconest
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Berinert
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Ruconest
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BerinertView full Berinert profile
RuconestView full Ruconest profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.